Cargando…
Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models
Allogeneic stem cell transplantation (allo-SCT) has become an important treatment modality for patients with high-risk acute myeloid leukemia (AML) and is also under investigation for soft tissue sarcomas. The therapeutic success is still limited by minimal residual disease (MRD) status ultimately l...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356002/ https://www.ncbi.nlm.nih.gov/pubmed/22655268 http://dx.doi.org/10.3389/fonc.2012.00032 |
_version_ | 1782233477832245248 |
---|---|
author | Rettinger, Eva Meyer, Vida Kreyenberg, Hermann Volk, Andreas Kuçi, Selim Willasch, Andre Koscielniak, Ewa Fulda, Simone Wels, Winfried S. Boenig, Halvard Klingebiel, Thomas Bader, Peter |
author_facet | Rettinger, Eva Meyer, Vida Kreyenberg, Hermann Volk, Andreas Kuçi, Selim Willasch, Andre Koscielniak, Ewa Fulda, Simone Wels, Winfried S. Boenig, Halvard Klingebiel, Thomas Bader, Peter |
author_sort | Rettinger, Eva |
collection | PubMed |
description | Allogeneic stem cell transplantation (allo-SCT) has become an important treatment modality for patients with high-risk acute myeloid leukemia (AML) and is also under investigation for soft tissue sarcomas. The therapeutic success is still limited by minimal residual disease (MRD) status ultimately leading to patients’ relapse. Adoptive donor lymphocyte infusions based on MRD status using IL-15-expanded cytokine-induced killer (CIK) cells may prevent relapse without causing graft-versus-host-disease (GvHD). To generate preclinical data we developed mouse models to study anti-leukemic- and anti-tumor-potential of CIK cells in vivo. Immunodeficient mice (NOD/SCID/IL-2Rγc(−), NSG) were injected intravenously with human leukemic cell lines THP-1, SH-2 and with human rhabdomyosarcoma (RMS) cell lines RH41 and RH30 at minimal doses required for leukemia or tumor engraftment. Mice transplanted with THP-1 or RH41 cells were randomly assigned for analysis of CIK cell treatment. Organs of mice were analyzed by flow cytometry as well as quantitative polymerase chain reaction for engraftment of malignant cells and CIK cells. Potential of CIK cells to induce GvHD was determined by histological analysis. Tissues of the highest degree of THP-1 cell expansion included bone marrow followed by liver, lung, spleen, peripheral blood (PB), and brain. RH30 and RH41 engraftment mainly took place in liver and lung, but was also detectable in spleen and PB. In spite of delayed CIK cell expansion compared with malignant cells, CIK cells injected at equal amounts were sufficient for significant reduction of RH41 cells, whereas against fast-expanding THP-1 cells 250 times more CIK than THP-1 cells were needed to achieve comparable results. Our preclinical in vivo mouse models showed a reliable 100% engraftment of malignant cells which is essential for analysis of anti-cancer therapy. Furthermore our data demonstrated that IL-15-activated CIK cells have potent cytotoxic capacity against AML and RMS cells without causing GvHD. |
format | Online Article Text |
id | pubmed-3356002 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Frontiers Research Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33560022012-05-31 Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models Rettinger, Eva Meyer, Vida Kreyenberg, Hermann Volk, Andreas Kuçi, Selim Willasch, Andre Koscielniak, Ewa Fulda, Simone Wels, Winfried S. Boenig, Halvard Klingebiel, Thomas Bader, Peter Front Oncol Oncology Allogeneic stem cell transplantation (allo-SCT) has become an important treatment modality for patients with high-risk acute myeloid leukemia (AML) and is also under investigation for soft tissue sarcomas. The therapeutic success is still limited by minimal residual disease (MRD) status ultimately leading to patients’ relapse. Adoptive donor lymphocyte infusions based on MRD status using IL-15-expanded cytokine-induced killer (CIK) cells may prevent relapse without causing graft-versus-host-disease (GvHD). To generate preclinical data we developed mouse models to study anti-leukemic- and anti-tumor-potential of CIK cells in vivo. Immunodeficient mice (NOD/SCID/IL-2Rγc(−), NSG) were injected intravenously with human leukemic cell lines THP-1, SH-2 and with human rhabdomyosarcoma (RMS) cell lines RH41 and RH30 at minimal doses required for leukemia or tumor engraftment. Mice transplanted with THP-1 or RH41 cells were randomly assigned for analysis of CIK cell treatment. Organs of mice were analyzed by flow cytometry as well as quantitative polymerase chain reaction for engraftment of malignant cells and CIK cells. Potential of CIK cells to induce GvHD was determined by histological analysis. Tissues of the highest degree of THP-1 cell expansion included bone marrow followed by liver, lung, spleen, peripheral blood (PB), and brain. RH30 and RH41 engraftment mainly took place in liver and lung, but was also detectable in spleen and PB. In spite of delayed CIK cell expansion compared with malignant cells, CIK cells injected at equal amounts were sufficient for significant reduction of RH41 cells, whereas against fast-expanding THP-1 cells 250 times more CIK than THP-1 cells were needed to achieve comparable results. Our preclinical in vivo mouse models showed a reliable 100% engraftment of malignant cells which is essential for analysis of anti-cancer therapy. Furthermore our data demonstrated that IL-15-activated CIK cells have potent cytotoxic capacity against AML and RMS cells without causing GvHD. Frontiers Research Foundation 2012-04-09 /pmc/articles/PMC3356002/ /pubmed/22655268 http://dx.doi.org/10.3389/fonc.2012.00032 Text en Copyright © 2012 Rettinger, Meyer, Kreyenberg, Volk, Kuçi, Willasch, Koscielniak, Fulda, Wels, Boenig, Klingebiel and Bader. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited. |
spellingShingle | Oncology Rettinger, Eva Meyer, Vida Kreyenberg, Hermann Volk, Andreas Kuçi, Selim Willasch, Andre Koscielniak, Ewa Fulda, Simone Wels, Winfried S. Boenig, Halvard Klingebiel, Thomas Bader, Peter Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models |
title | Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models |
title_full | Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models |
title_fullStr | Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models |
title_full_unstemmed | Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models |
title_short | Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models |
title_sort | cytotoxic capacity of il-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356002/ https://www.ncbi.nlm.nih.gov/pubmed/22655268 http://dx.doi.org/10.3389/fonc.2012.00032 |
work_keys_str_mv | AT rettingereva cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT meyervida cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT kreyenberghermann cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT volkandreas cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT kuciselim cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT willaschandre cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT koscielniakewa cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT fuldasimone cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT welswinfrieds cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT boenighalvard cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT klingebielthomas cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels AT baderpeter cytotoxiccapacityofil15stimulatedcytokineinducedkillercellsagainsthumanacutemyeloidleukemiaandrhabdomyosarcomainhumanizedpreclinicalmousemodels |